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Abstract
Experiments dating back to the 1940’s have led to the hypothesis that the brain is an immunologically privileged site,
shielding its antigens from immune recognition. The paraneoplastic Hu syndrome provides a powerful paradigm for
addressing this hypothesis; it is believed to develop because small cell lung cancers (SCLC) express the neuron-specific Hu
protein. This leads to an Hu-specific tumor immune response that can develop into an autoimmune attack against neurons,
presumably when immune privilege in the brain is breached. Interestingly, all SCLC express the onconeural HuD antigen,
and clinically useful tumor immune responses can be detected in up to 20% of patients, yet the paraneoplastic neurologic
syndrome is extremely rare. We found that HuD-specific CD8+ T cells are normally present in the mouse T cell repertoire, but
are not expanded upon immunization, although they can be detected after in vitro expansion. In contrast, HuD-specific T
cells could be directly activated in HuD null mice, without the need for in vitro expansion. Taken together, these results
demonstrate robust tolerance to the neuronal HuD antigen in vivo, and suggest a re-evaluation of the current concept of
immune privilege in the brain.
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Introduction
Immune tolerance to self antigens is believed to protect against
autoimmunity, but not in the central nervous system (CNS), which
has been widely accepted to be an immune privileged site since
Medawar discovered that transplanted allografts were rejected in
the body but survived in the CNS [1,2]. This idea was reinforced
when it was recognized that the blood-brain barrier, the absence
of lymphatics in the CNS, and the expression of immunosuppres-
sive cytokines and death receptors all serve to protect the brain
from potentially harmful inflammatory responses [3,4]. The
mechanisms that might underlie CNS immune privilege have
been periodically redefined as new ways of maintaining tolerance
have been discovered, and as it has been recognized that CD8+ T
cells can infiltrate the brain [5], but the idea remains that the
immune system is restricted from seeing brain specific cellular
antigens [2]. Although soluble brain antigens readily gain access to
the draining cervical lymph nodes where they are taken up by
antigen presenting cells, no such pathway has been defined for
cellularly-restricted proteins [6,7]. The immune system, it would
seem, is ignorant of antigens sequestered within neurons,
providing an explanation of how the brain is protected from
potentially damaging autoimmune disease.
The paraneoplastic neurologic diseases (PND) provide an
important model of immunity to brain-specific antigens. For
example in the Hu paraneoplastic syndrome, patients experience
neurologic symptoms that may affect the dorsal root ganglia,
limbic system, cerebellum, and brainstem. The neurologic
symptoms develop in patients who have small cell lung cancer
(SCLC), tumors that express the HuD antigen, and patients
generate impressive tumor immunity to this otherwise aggressive
malignancy. SCLCs from Hu patients are usually limited to single
nodules, and are typically discovered only after presentation of
neurologic symptoms [8,9]. A link between the neurologic
symptoms and tumor immunity in the disorder was made by
Posner and colleagues, who discovered that these patients harbor
high titer antibodies to HuD, a normally neuron-specific RNA
binding protein that is also expressed by SCLC cells [10–12]. A
general model for the disorder has been that the normally neuron-
specific expression of the HuD antigen, combined with immune
privilege in the brain, accounts for the immunogenicity of the
HuD antigen when it is ectopically expressed in SCLC [13].
However, the nature of such immune privilege is poorly
understood, and may not explain all aspects of the disorder. For
example, even though all SCLC express HuD [11], only some
patients make an immune response to the tumor (20%), and very
few go on to develop PND [14], as diagnosed clinically and
confirmed by the presence of high titer anti-HuD antibodies in the
serum and cerebrospinal fluid. While these observations suggest
the possibility that there may be mechanisms responsible for
inhibiting autoimmunity to HuD, they would also conflict with the
idea of immune privilege to neuron-restricted antigens.
The presence of antibodies to Hu in the blood and
cerebrospinal fluid are important diagnostic markers for the
disorder. However several observations have suggested a T cell
mediated component to the PNDs [13]. The Hu proteins are
sequestered intracellularly within neurons, activated T cells are
present in the cerebrospinal fluid of Hu patients, and the immune
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and IgG1 antibodies present in circulation [15,16]. All attempts to
create mouse models of the disease by immunizing with whole
HuD protein have failed to induce neuronal degeneration despite
the generation of high titer antibodies to Hu. Moreover, CD8 T
cells have been shown to play an important role in the
pathogenesis of another form of PND, paraneoplastic cerebellar
degeneration [17,18]. Nonetheless, efforts to identify HuD-specific
T cells in SCLC patients with the Hu syndrome have yielded
mixed results. Some investigators have reported negative results
[19], while others have found inconsistent evidence for such cells
specific to affected patients [20–22], or the presence of atypical T
cells [23]. To examine the nature of the immune response to HuD,
we have studied HuD-specific CD8 T cells in the mouse, and




Wild type C57BL/6 and Rag1
2/2 (stock no. 00216) mice were
purchased from The Jackson Laboratory. HuD
2/2 mice [24] (76
backcrossed onto the C57BL/6 background) were obtained from
H. Okano.
Ethics Statement. All animals were handled in accordance
with animal husbandry guidelines established and reviewed by the
Rockefeller University Institutional Animal Care and Use
Committee (IACUC), which complies with federal and state
regulations that concern the use of experimental animals.
HuD Peptide Screen
C57BL/6 mice were injected in the right footpad with 125 ug of
a single HuD peptide emulsified in TiterMax adjuvant. On day 7,
CD8+ T cells were isolated from the right popliteal and inguinal
lymph nodes by MACS purification (Miltenyi Biotec) and plated in
a 20 hour IFNc ELISPOT assay at 2610
5 CD8+ T cells per well.
EL4 cells were added as stimulators at 5610
4 per well with 10 uM
peptide.
Immunizations
For immunization with recombinant adenovirus, 6–8 week old
mice were injected with 100 ul purified adenovirus (10
9 PFU/mL)
i.d. and treated with Pertussis Toxin (Sigma) at days 0 and 2. For
immunization with influenza virus, 6–8 week old C57BL/6 mice
were injected i.p. with 300 H.A.U. of influenza A/PR/8.
Preparation of primary murine kidney cells
Kidney cells from adult mice in single cell suspension were
plated in 10 cm dishes in D-10 (DMEM supplemented with 10%
FBS, nonessential amino acids, sodium pyruvate, glutamine, 22-
ME, gentamicin). Cultures were fed by replacing D-10 on days 4
and 7. On day 7, recombinant mouse IFNc (R & D Systems) was
added at 10 U/mL. On day 8, 10 ul recombinant adenovirus at
10
9 PFU/mL was added the cells were harvested on day 9 for use
in an IFNc Elispot assay.
Mouse CD8+ T cell stimulation
For in vitro stimulation, 2.5–3610
7 splenocytes from adenovirus-
immunized mice were incubated at 37uC in upright T25 culture
flasks (Corning) in R-10 with 0.5 uM peptide for 7 days. For
further rounds of restimulation, splenocytes were plated in 24 well
plates (2–6610
5 splenocytes per well) with peptide-pulsed feeder
cells in R-10 with 50 CU/mL recombinant human IL-2 (Chiron).
Feeder cells were prepared from spleens of naı ¨ve syngeneic mice
by pulsing with 0.5 uM peptide for 1 hour at room temperature
and irradiating at 3,000 Rads before plating.
Adoptive transfer
For adoptive transfer experiments, mice received i.v. injections
of 7 day in vitro stimulated CD8+ T cells (5610
6 CD8+/mouse)
and DCs pulsed with peptide (2610
6 DC/mouse) along with IL-2
(6 injections of 10
5 CU/mouse i.p. every 12 hours) and Pertussis
Toxin (400 ng/mouse i.p. on days 0 and 2). CD8+ cells were
isolated from stimulation cultures by negative selection using a
CD8+ T cell isolation kit (Miltenyi Biotec). Mature DCs were
pulsed with 100 uM peptide in R-10 and incubated at room
temperature for 1 hour, shaking every 15 minutes. The cells were
then washed twice and resuspended at 10
7/mL in RPMI 1640 for
i.v. injection.
Mouse DC preparation
Bone marrow-derived DCs were prepared as previously
described [25]. On day 7, DCs were matured for 2 days with
125 ng/mL recombinant mouse TNFa (R&D Systems).
Tetramer staining
Data using surface antibodies (Becton Dickinson) and PE-
labeled tetramers (Immunomics iTAg MHC Tetramer, Beckman
Coulter) was acquired with a FACScaliber (Becton Dickonson).
In Vivo CTL assay
Mice received a single i.v. injection of target cells. Targets
consisted of two peptide-pulsed populations of CFSE-labeled
syngeneic splenocytes in a 1:1 ratio: CFSE
lo syngeneic splenocytes
labeled with 0.5 uM CFSE and CFSE
hi syngeneic splenocytes
labeled with 5 uM CFSE. One population was pulsed with 10 uM
HuD p321 peptide and the other with 10 uM bgal p96 peptide.





hi targets). 7 hours after target injection, the spleens were
removed and the amount of CFSE
lo versus CFSE
hi targets was
quantitated by flow cytometry.
Elispot assay
CD8+ cells were isolated from spleens or lymph nodes of
immunized mice using MACS purification (Miltenyi Biotec). T
cells were added to IFNc ELISPOT plates at the indicated
concentrations along with stimulators and incubated for 20 hours.
Cells were washed out of the ELISPOT plate using a mild
detergent followed by incubation with 1 ug/mL biotin-conjugated
anti-IFNc mAb. Wells were developed using the Vectastain Elite
Kit according to the manufacturer’s instructions (Vector Labora-
tories). The ELISPOT plate evaluation was performed by an
independent evaluation service (Zellnet Consulting) using an
automated ELISPOT reader (Carl Zeiss).
RMA/S Assay
RMA/S stabilization assay was performed as previously
described [26].
Results
Comprehensive screen to identify potential mouse H-2b
HuD epitopes
To determine if HuD-specific CD8 T cells could be detected in
the mouse H-2
b repertoire, we performed a comprehensive screen
of the entire HuD peptide library in C57BL/6 mice. The HuD
peptide library consisted of 386 overlapping nonamers, including
Tolerance to the Hu Antigen
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ensure that all HuD peptide-specific CD8 T cell clones present in
the H-2
b repertoire could expand, mice were immunized
subcutaneously in the footpad with each individual HuD peptide
emulsified in TiterMax adjuvant. CD8 T cells isolated from the
draining lymph nodes were assessed for their ability to secrete
IFNc in response to cognate peptide-pulsed syngeneic stimulators
(Fig 1a). These experiments identified 7 potential HuD CD8 T cell
epitopes (Fig 1b).
Identification of the immunodominant H-2b HuD
epitope
We sought to identify immunodominant CD8 T cell epitopes
from the 7 candidate HuD peptides. Mice were immunized with
replication-deficient recombinant adenovirus expressing full length
HuD to allow for in vivo processing and presentation of HuD
peptides onto MHC I molecules, and splenocytes from immunized
animals were stimulated in vitro for 7 days with each peptide. Of
the 7 potential HuD epitopes, peptides 296 and 321 were able to
prime CD8 T cells to secrete IFNc after adenovirus-HuD
immunization (Fig 1c). These CD8 T cell responses were not the
result of in vitro priming, since HuD peptides failed to elicit IFNc
secretion from mice immunized with a control antigen (adenovi-
rus-b-gal; Fig 1d). Subsequent assays comparing HuD p296-
specific and p321-specific CD8 T cells indicated that p296-specific
CD8 T cells are low affinity cells, difficult to propagate in vitro,
whereas p321-specific CD8 T cells can be reproducible and stably
maintained in culture (data not shown), and we therefore focused
on the latter.
Characterization of HuDp321-specific CD8 T cells
In order to assess whether HuD p321-specific CD8 T cells were
able to lyse target cells in an antigen dependent manner, we
performed an in vivo cytotoxic T lymphocyte (CTL) assay (Fig 2). In
vitro stimulated HuD p321-specific CD8 T cells were adoptively
transferred intravenously into a syngeneic host and assessed for
their ability to lyse a population of peptide-pulsed target cells. In
order to enhance the effector function of our transferred T cells,
we co-injected mature C57BL/6 dendritic cells (DC) pulsed with
p321 into hosts. We assessed target lysis in two different strains of
mice: wild type C57BL/6 mice and Rag
2/2 mice. Transferred
HuD-specific CD8 T cells were potent cytotoxic effectors in both
strains, exhibiting 88% and 74% specific lysis of targets in Rag
2/2
mice (Fig 2a) and wild type mice (Fig 2b), respectively. Adoptive
transfer of HuD p321-specific CD8 T cells together with DC
pulsed with irrelevant peptide into Rag
2/2 mice yielded a lower
level of in vivo cytotoxicity (20%; data not shown), suggesting that
the DC pulsed with p321 served to expand the adoptively
transferred population of HuD specific CD8 T cells in recipient
mice. These results demonstrate that after activation by immuni-
Figure 1. p321 is the immunodominant CD8+ T cell epitope of
HuD. (a) A representative peptide screen of 16 HuD peptides.
Individual or duplicate C57BL/6 mice were immunized with a single
HuD peptide emulsified in TiterMax adjuvant. 7 days later, CD8+ T cells
were harvested from draining lymph nodes and plated in an IFNc
ELISPOT assay (2610
5/well) with EL4 cells pulsed with 10 uM cognate or
irrelevant peptide (5610
4/well). The assay was performed in triplicate.
Means are plotted and error bars represent standard deviations of the
mean. Positive peptides were re-screened in triplicate mice. (b) 7
peptides (in bold) were identified as potential CD8+ epitopes from the
HuD protein sequence. (c) C57BL/6 mice were immunized with AdVHuD
plus PTx. 13 days after immunization, splenocytes were divided into 8 in
vitro stimulation cultures and stimulated with each of the 7 HuD
peptides or bgal p96. CD8+ T cells were purified from stimulation
cultures and plated (10
4 T cells/well) with cognate or irrelevant peptide-
pulsed irradiated EL4 cells (5610
4/well) in an IFNc ELISPOT assay. The
assay was performed in triplicate. Means are plotted and error bars
represent standard deviations of the mean. Data is representative of
three experiments. (d) As a control for in vitro priming, C57BL/6 mice
were immunized with AdVbgal+PTx and stimulated in vitro with each of
the 7 potential HuD epitopes or bgal p96 and assayed for IFNc secretion
as in (c).
doi:10.1371/journal.pone.0005739.g001
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able to function as cytotoxic effectors in vivo.
We defined the MHC restriction of HuD p321-specific CD8 T
cells in order to design tetramers able to bind their T cell
receptors. p321 was predicted to bind D
b MHC I on the basis of its
amino acid sequence (http://www.syfpeithi.de/). To formally
assess the MHC I restriction, we took advantage of the H2
bm1
mouse strain, which expresses a mutated form of the K
b allele.
HuD p321-specific CD8 T cells were able to respond to both wild
type and H2
bm1 cells pulsed with cognate peptide (Fig 2c). In
contrast, b-galp96-specific CD8 T cells recognized peptide-pulsed
wild type cells but not H2
bm1 cells pulsed with cognate peptide,
since the p96 epitope is K
b-restricted. These results confirm that
p321 is presented on D
b MHC I.
We were then able to generate a D
b-p321 tetramer that bound
to HuD-specific CD8+ T cells (data not show, and Fig. 2d). We
used this tetramer to monitor the expansion of HuD-specific
CD8+ T cells after immunization with adenovirus-HuD. For
comparison, mice were immunized with influenza virus to track
the expansion of NP-specific CD8+ T cells (NP is an influenza
epitope that binds D
b MHC I). When we measured the frequency
of NP-specific CD8+ T cells directly ex vivo, we observed an
expected frequency of NP-specific T cells (1.5% of the total CD8+
T cell repertoire), and this population was further expanded upon
in vitro stimulation with NP (Fig 2d). We also found a similar degree
of expansion of b-gal-specific CD8+ T cells directly after
immunization with adenovirus-b-gal (data not shown). In contrast,
after immunization with adenovirus-HuD we saw almost no
detectable proliferation of HuD p321-specific CD8+ T cells
directly ex vivo. Strikingly, however, we were able to expand the
population of HuD p321-specific CD8+ T cells upon in vitro
stimulation to 1.4% of total CD8+ T cells (Fig 2d). The
proliferation of HuD-specific T cells depended on the presence
of antigen in vivo, since naı ¨ve splenocytes did not expand after in
vitro stimulation with p321. Thus, T cells specific for the neuronal
antigen HuD do not respond to antigen in a similar manner as T
cells specific for a neoantigen; after immunization with adenovirus-
HuD, CD8+ T cells are not detectable directly ex vivo, but are after
in vitro expansion, suggesting that their expansion is suppressed in
vivo.
Pertussis toxin and in vitro stimulation are required for
HuD-specific CD8+ T activation
To assess the functional status of HuD-specific CD8+ T cells we
compared their ability to produce IFNc after priming in vivo. Mice
were immunized with adenovirus-HuD or adenovirus-b-gal in
combination with pertussis toxin, which was used as an adjuvant to
boost the HuD-specific T cell response, and CD8+ T cell IFNc
secretion activation was measured directly ex vivo. After immuni-
zation with adenovirus-b-gal we saw robust IFNc secretion by b-
gal p96-specific CD8+ T cells. In contrast, we saw no IFNc
secretion by HuD p321-specific CD8+ T cells directly ex vivo after
immunization with adenovirus-HuD and pertussis toxin (Fig. 3a).
When splenocytes from these immunized mice were stimulated in
vitro, we then detected IFNc secretion (Fig. 3b), indicating that
these cells were able to recognize antigen in vivo, but were
prevented from becoming effector cytotoxic T cells. Interestingly,
no IFNc secretion was detected after in vitro stimulation of
splenocytes from mice immunized with adenovirus-HuD in the
absence of pertussis toxin. The dependence on both pertussis toxin
and in vitro stimulation for the activation of HuD-specific CD8+ T
cells suggests that mice may be tolerized to the HuD protein since
their activation requires both additional adjuvant and expansion in
vitro.
Mice are tolerized to HuD
To assay for tolerance to HuD, we immunized HuD-deficient
mice [24] (HuD
2/2) or wild-type littermates (HuD
+/+) with
adenovirus-HuD plus pertussis toxin and looked for IFNc
secretion by HuD p321-specific CD8+ T cells directly ex vivo.
Whereas HuD
+/+ mice were unable to generate activated HuD
p321-specific cells after immunization, HuD
2/2 mice generated
strong HuD p321-specific CD8+ T cell responses directly ex vivo
(Fig 3c). To assess whether the lack of an ex vivo response in HuD
+/
+ mice was due to ineffective immunization, splenocytes stimulated
in vitro with p321 were assayed and found to be competent to
generate activated HuD p321-specific CD8+ T cells (Fig 3d). The
ability to prime this robust ex vivo HuD-specific T cell response in
mice lacking the HuD antigen, in contrast with the inability of
wild-type animals to activate HuD-specific CD8+ T cells in the
absence of pertussis toxin plus in vitro stimulation, supports the
conclusion that wild-type mice are tolerized to the neuronal
antigen HuD.
We compared the CD8+ T cell response to HuD and HuA, a
closely related Hu-family member that is expressed ubiquitously
throughout the body. In the p321 region of the two proteins, HuA
differs from HuD at a single amino acid residue (Fig 4a), although
the anchor residues that stabilize the peptide-MHC interaction are
conserved between the two peptides, suggesting that they might
bind MHC I with similar affinity. We tested the affinities of HuA
p321 versus HuD p321 for MHC I using RMA/S cells incubated
with serial dilutions of peptide (Fig 4b). HuA p321 had a higher
avidity for Db MHC I compared to HuD p321, and HuD p321
bound D
b with similar affinity to the control peptide NP. To
determine if HuA p321-specific CD8+ T cells are present in the H-
2
b repertoire, we immunized C57BL/6 mice with peptide
emulsified in TiterMax and looked seven days later for IFNc
secretion by CD8+ T cells plated with peptide-pulsed stimulators.
Whereas both HuD p321-specific T cells and NP-specific T cells
were detectable by IFNc secretion, no HuA p321-specific T cells
Figure 2. Characterization of HuD p321-specific CD8+ T. (a) 5610
6 HuD p321-specific in vitro stimulated CD8+ T cells were adoptively
transferred into Rag
2/2 mice (n=2) with 2610
6 C57BL/6 DC pulsed with p321. Mice also received PTx and IL-2. Eight days post transfer, mice were
injected with CFSE-labeled syngeneic splenocytes pulsed with HuD p321 (CFSE
hi)o rbgal p96 (CFSE
lo). A naı ¨ve control mouse without transferred
CD8+ T cells was injected with CFSE-labeled splenocytes. 6 hours after target injection, splenocytes were analyzed by FACS for in vivo target cell lysis.
A representative mouse is shown. Data is representative of two experiments. (b) C57BL/6 mice (n=2) were used as recipients of adoptively
transferred HuD p321-specific CD8+ T cells as in (a). A representative mouse is shown. Data is representative of two experiments. (c) Primary kidney
cells from C57BL/6 mice (D
b+/K
b+) or transgenic Bm1 mice (D
b+/K
b2) were irradiated and pulsed with HuD p321 or bgal p96 and used as stimulators
in an IFNc ELIPOST assay (5610
4/well) with 36restimulated HuD p321-specific or bgal p96-specific CD8+ T cells (10
4/well). The assay was performed
in triplicate. Means are plotted and error bars represent standard deviations of the mean. Data is representative of two experiments. (d) C57BL/6 mice
were immunized with either AdVHuD or influenza virus or left untreated (2 mice per group). 15 days after immunization, CD8+ T cells were isolated
from the spleen and stained directly ex vivo with anti-CD8+ antibody and PE-labeled tetramer. A portion of splenocytes from each mouse was
stimulated in vitro with cognate peptide for 7 days. Naı ¨ve mice were stimulated with HuD p321. CD8+ T cells from in vitro stimulation cultures were
stained with anti-CD8+ antibody and PE-labeled tetramer. Plots are gated on CD8+ T cells. Data is representative of two experiments.
doi:10.1371/journal.pone.0005739.g002
Tolerance to the Hu Antigen
PLoS ONE | www.plosone.org 5 June 2009 | Volume 4 | Issue 6 | e5739could be detected (Fig 4c). These results suggest that T cells
specific to the peripheral HuA protein have been deleted from the
repertoire or are subject to a more complete and irreversible form
of tolerance relative to HuD-specific T cells. Conversely, the
ability to detect HuD p321-specific CD8+ T cells confirms that
these cells are not deleted by a central tolerance mechanism.
Discussion
Autoimmune attack against neurons is particularly detrimental,
since neurons have limited capacity for regeneration and damage
may therefore be permanent. This is clearly the case in the PNDs,
where the clinical outcome in these cancer patients is typically
determined by the neurologic disease. In the severest forms of the
Hu syndrome, patients survive an average of only 7 months from
the onset of their illness. Dogma in the past ,60 years has been
that the immune system is ignorant to neuron-specific proteins
such as the Hu antigen. However, it has become clear that the
HuD antigen, as well as other PND antigens, may be commonly
expressed outside of neurons in common cancer types (all small
cell lung cancers express HuD, and over half of ovarian cancers
express cdr2) [27]. Although only rare subsets of these cancer
patients ever develop PND, it would seem that reliance on
ignorance of neuronal proteins would pose a potentially great
immunologic risk, as neurons induce MHC I molecules during
inflammation, at the same time that activated T cells are allowed
entry to the CNS across the blood brain barrier [3,5,28,29]. In
setting out here to look for HuD-specific T cell responses we have
discovered an unexpected resolution to these conflicting points by
finding that there is strong tolerance to the HuD protein in normal
resting mice. Tolerance to HuD was confirmed by finding that
HuD-deficient mice generate functional HuD p321-specific CD8+
T cells directly ex vivo, without the need for in vitro stimulation with
peptide. This tolerance was functionally relevant, as mice
examined after receiving HuD immunizations or at various times
after HuD CD8+ T cell adoptive transfer (9 days, 18 days, one
month) did not develop evidence of neurologic dysfunction or
abnormalities evident by immunohistochemical studies of brain
sections.
The presence of HuD p321-specific CD8+ T cells in the H-2
b
repertoire indicates that these cells are either not subject to central
tolerance induction in the thymus, or exist as a result of incomplete
central tolerance. Extensive examination of HuD expression in the
adult mouse has failed to find protein in the thymus or any other
Figure 3. C57BL/6 mice are tolerized to HuD. (a) C57BL/6 mice
were immunized with AdVHuD or AdVbgal+PTx (2 mice per group). 13
days later, CD8+ T cells were isolated from the spleen and plated in an
IFNc ELISPOT assay (2610
5/well) with EL4 pulsed with 10 uM peptide
(5610
4/well). The assay was performed in triplicate. Means are plotted
and error bars represent standard deviations of the mean. Data is
representative of four experiments. (b) C57BL/6 mice were immunized
with AdVHuD2/+PTx (2 mice per group). 13 days later, splenocytes
were stimulated in vitro with 0.5 uM HuD p321. On day 7, CD8+ T cells
were plated in an IFNc ELISPOT assay (10
4/well) with DC pulsed with
10 uM peptide (7610
3/well). The assay was performed in triplicate.
Means are plotted and error bars represent standard deviations of the
mean Data is representative of two experiments. (c) Individual HuD
+/+
or HuD
2/2 mice were immunized with AdVHuD+PTx and used in an
IFNc ELISPOT assay as described in (a). The assay was performed in
triplicate. Means are plotted and error bars represent standard
deviations of the mean. Data is representative of four experiments.
(d) Half of the spleens from mice immunized in (c) were stimulated in
vitro with HuD p321. After 7 days, CD8+ T cells were isolate from
stimulation cultures and plated in an IFNc ELISPOT (10
4/well) with
peptide pulsed EL4 cells (5610
4/well).
doi:10.1371/journal.pone.0005739.g003
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appear to be regulated by the AIRE protein [31]. In addition, we
immunized AIRE KO mice with adenovirus-HuD and saw no
HuD p321 specific T cell directly ex vivo (data not shown). In
contrast, when we compared the CD8+ T cell response to HuD
p321 versus its homologous epitope in HuA, we found that HuA
p321-specific CD8+ T cells were not detected after TiterMax
immunization, suggesting that they were centrally deleted. Given
HuA’s ubiquitous expression pattern, central tolerance would be
important to prevent the development of widespread peripheral
autoimmunity, which is not observed in HuD patients. In contrast,
HuD p321-specific CD8+ T cells were present in the repertoire;
moreover, the IFNc response of HuD p321-specific T cells was
comparable in magnitude to that elicited from neoantigen-specific
T cells after Titermax-peptide immunization. While this experi-
ment was done with a high concentration of peptide (1610
25 M),
which could have obscured low affinity T cell responses, we found
that the affinity of restimulated HuD and bgal T cells were
comparable (in peptide ELISPOT titration assays, both recog-
nized targets pulsed with dilutions of peptide down to 1610
29 M;
data not shown). Taken together, our data point to the possibility
that mice normally have a mechanism for maintaining active
tolerance to a neuron-specific protein.
The maintenance of tolerance, either by regulatory T cells or
through induction of anergy of CD8+ T cells in the periphery,
requires a means for antigen to be captured and presented to
antigen presenting cells (APCs), which themselves make no
detectable HuD mRNA (unpublished data). Given the restricted
expression of HuD to neurons, which do not turnover in the steady
state, the means of sustaining peripheral tolerance to HuD would
seem dependent on either ectopic expression of the protein by a
non-neuronal cell type, or cross presentation of HuD by an APC.
Examination of HuD expression in adult mouse tissue has
confirmed its restriction to neurons [30] (Darnell et al.,
unpublished data), although it is difficult to exclude the possibility
that an undetectable amount of protein may have escaped
detection in these negative results. Recently, ectopic expression
of peripheral-tissue antigens by lymph node stromal cells was
reported [32]. In this transgenic mouse model, a cytosolic form of
ovalbumin (OVA) under the control of a tissue-specific promoter
was shown to be endogenously processed and presented onto
MHC I molecules by a stromal cell population in the lymph node
cortex. Endogenous presentation of OVA in the lymph node was
an effective means of inducing tolerance in naı ¨ve OT-I CD8+ T
cells. Circulating HuD-specific CD8+ T cells may be subject to a
similar form of regulation if ectopic expression of HuD by lymph
node cells resulted in presentation of HuD p321 peptide
complexes, although we have no expression data to support such
a speculation.
Soluble CNS antigens may drain to cervical lymph nodes, and
proteins in the CNS can readily access lymphoid tissues via the
CSF and cervical lymphatics for processing and presentation to the
immune system [2,29,33,34]. However, it is not clear that this
pathway is relevant to an intracellular neuronal protein like HuD.
Another possibility is that phagocytosis of HuD-expressing
neurons, or fragments of neurons such as remodeling synapses,
could provide a means for antigen entry into an APC. While whole
neurons may not be a likely form of antigen for APCs given their
limited ability to turn-over, APCs may be able to phagocytose
membrane-bound neuronal blebs for cross presentation and
subsequent tolerance induction, in a manner analogous to their
general ability to cross-present antigen from apoptotic cells
[18,35]. For example, outer segments of photoreceptors, normally
phagocytosed by retinal pigment epithelium, may instead be
phagocytosed by microglia following transplantation into the brain
[36,37].
We have shown that a protein confined in expression to neurons
is not ignored by the immune system but undergoes tolerance
induction in order to prevent against autoimmunity directed at the
nervous system. The maintenance of tolerance to HuD is
apparently quite effective, given that all SCLC express the HuD
antigen but only a very small (0.01%) population of patients
succumbs to neuronal degeneration. Tolerance to HuD suggests
revisiting the model of the brain as an immune privileged organ.
Rather, we suggest the opposite possibility, that there exists a
natural mechanism that acts in the steady state, similar to what
occurs with peripheral tissue antigens [38], but that is perhaps
even more profound, to tolerize T cells to brain antigens as a
default, and for the same end purpose—to keep the organ from
Figure 4. Comparison of HuA p321-specific CD8+ T cells and
HuD p321-specific CD8+ T cells. (a) Sequences of HuD p321 and
HuA p321 (b) RMA/S cells were incubated with serial dilutions of
peptide and stained for D
b MHC I. HuD p321 and HuA p321 were
assayed. The A2.1 epitope of influenza (M1) was used as a negative
control. The D
b epitope of influenza (NP) was used as a positive control.
(c) C57BL/6 mice were immunized with individual peptides (NP, HuA
p321, or HuD p321) in TiterMax adjuvant (2 mice per group). 7 days
later, draining lymph node CD8+ T cells were plated in an IFNc ELISPOT
assay (2610
5/well) with peptide pulsed EL4 cells (5610
4/well). The assay
was performed in triplicate. Means are plotted and error bars represent
standard deviations of the mean. Data is representative of four
experiments.
doi:10.1371/journal.pone.0005739.g004
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studies may be explained by immunologic tolerance to brain
antigens, even newly transplanted antigens, rather than by
immunologic ignorance as originally suggested.
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